Log in

ASX:CYCCyclopharm Stock Price, Forecast & News

-0.01 (-0.73 %)
(As of 05/13/2020)
Today's Range
Now: A$1.36
50-Day Range N/A
52-Week Range
Now: A$1.36
Volume10,000 shs
Average VolumeN/A
Market Capitalization$107.79 million
P/E RatioN/A
Dividend Yield0.64%
Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The company offers diagnostic equipment and consumables, which are used by physicians in the detection of pulmonary embolism. It also provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases; and Ultralute, a patented nuclear medicine technology for use in Mollybdenum-99 generators. The company serves nuclear medicine departments in hospitals and clinics. Cyclopharm Limited is headquartered in Kingsgrove, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 1.7Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars

Industry, Sector and Symbol

Industry Medical Devices
Phone61 2 9541 0411



Sales & Book Value

Annual Sales$17.01 million
Cash FlowA$0.16 per share
Book ValueA$0.30 per share



Market Cap$107.79 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CYC News and Ratings via Email

Sign-up to receive the latest news and ratings for CYC and its competitors with MarketBeat's FREE daily newsletter.

Cyclopharm (ASX:CYC) Frequently Asked Questions

How often does Cyclopharm pay dividends? What is the dividend yield for Cyclopharm?

Cyclopharm announced a Final dividend on Thursday, February 27th. Stockholders of record on Tuesday, April 7th will be given a dividend of 0.005 per share on Tuesday, April 7th. This represents a dividend yield of 0.52%. The ex-dividend date of this dividend is Monday, March 30th. View Cyclopharm's dividend history.

Has Cyclopharm been receiving favorable news coverage?

Media coverage about CYC stock has been trending negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cyclopharm earned a coverage optimism score of -2.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutCyclopharm.

Who are some of Cyclopharm's key competitors?

Who are Cyclopharm's key executives?

Cyclopharm's management team includes the following people:
  • Mr. James S. McBrayer, CEO, MD, Company Sec. & Director (Age 54)
  • Mr. Mathew Farag, Chief Operating Officer
  • Mr. Graham N. Phillips, Fin. Mang.
  • Ms. Sui Ling Cheah, Financial Controller (Age 49)
  • Mr. Lynn McLauchlin, Gen. Mang. of Canada

What is Cyclopharm's stock symbol?

Cyclopharm trades on the ASX under the ticker symbol "CYC."

What is Cyclopharm's stock price today?

One share of CYC stock can currently be purchased for approximately A$1.36.

How big of a company is Cyclopharm?

Cyclopharm has a market capitalization of $107.79 million and generates $17.01 million in revenue each year.

What is Cyclopharm's official website?

The official website for Cyclopharm is www.cyclopharm.com.au.

How can I contact Cyclopharm?

The company can be reached via phone at 61 2 9541 0411.

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.